Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second-Line Albuvirtide-Based 2-Drug Regimen Non-Inferior to 3-Drug Standard Therapy: Presented at IAS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Affiris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AFFiRiS and Frontier Biotechnologies Announce License Agreement for AFFITOPE\u00aeAT04, an Active Immunotherapy Targeting PCSK9 to Treat Hypercholesterolemia, in Greater China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (MPRO) Small Molecule Inhibitor, Laying Foundation for The Treatment of Acute and Long Covid","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Frontier Biotechnologies

    Menu

    Frontier Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Frontier Biotechnologies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (MPRO) Small Molecule Inhibitor, Laying Foundation for The Treatment of A...

              Details:

              FB2001 (bofutrelvir) has demonstrated in vivo antiviral activity in the lung and brain tissue of SARS-CoV-2 mouse model without the need for pharmacokinetic boosting.

              Lead Product(s): Bofutrelvir

              Therapeutic Area: Infections and Infectious Diseases Product Name: FB2001

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Frontier Biotechnologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AFFiRiS and Frontier Biotechnologies Announce License Agreement for AFFITOPE®AT04, an Active Immunotherapy Targeting PCSK9 to Treat Hypercholesterolemia, in Greater China

              Details:

              Subject to the terms of the agreement, Frontier Biotechnologies will be responsible for all development costs for AFFITOPE® AT04 occurring in Greater China and will receive the rights to develop, manufacture and exclusively commercialize AT04 in the licensed territory.

              Lead Product(s): Affitope AT04,Aluminium Oxyhydroxide

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Affitope AT04

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Affiris

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Frontier Biotechnologies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Second-Line Albuvirtide-Based 2-Drug Regimen Non-Inferior to 3-Drug Standard Therapy: Presented at IAS

              Details:

              The results of the randomized controlled, open-labelled, multicenter, non-inferiority study showed successful achievement of the primary endpoint, with a good proportion of patients on the ABT regimen with HIV RNA less than 50 copies/mL at 48 weeks.

              Lead Product(s): Albuvirtide,Lopinavir,Ritonavir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Aikening

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY